Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus .
[Read the full article here]Related News:
Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant …
Stem Cell Study Seeks To Wean Non-Related Transplant Recipients From Anti-Rejection Drugs